Class Action Certification YASMIN® & YAZ® Sold in Canada (Excluding Ontario and Québec)
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nov 29, 2018--A class action, Dembrowski v. Bayer Inc., QBG 1611 of 2009, commenced in the Court of Queen’s Bench for Saskatchewan, was certified to advance claims regarding the combination oral contraceptives Yasmin® and Yaz® that Bayer marketed in Canada.
The class includes Canadian women outside of Ontario and Quebec who were prescribed and ingested Yasmin® and Yaz® before October 4, 2016 and later had arterial or venous thromboembolism or gallbladder disease. Qualifying members of their family may have a claim under provincial family compensation legislation.
The class action alleges that Bayer failed to warn that Yasmin® and Yaz® posed a greater risk of causing thromboembolism and gallbladder disease than other available oral contraceptives. The allegations in the class action have not yet been proven in court, and Bayer denies any wrongdoing.
The Representative Plaintiff is represented by Merchant Law Group LLP. Class members can see the court approved notice, including information on how to participate or exclude themselves from the class action, at www.yazyasminclassaction.ca.
This Media Release was approved by Order of the Court of Queen’s Bench for Saskatchewan for delivery by Trilogy Class Action Services, 7B Pleasant Blvd, P.O. Box 1022, Toronto, Ontario, M4T 1K2, 1 (866) 329-7153, firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181129005020/en/
CONTACT: Trilogy Class Action Services
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL PROFESSIONAL SERVICES LEGAL
SOURCE: Trilogy Class Action Services
Copyright Business Wire 2018.
PUB: 11/29/2018 07:00 AM/DISC: 11/29/2018 07:01 AM